Clinical Trials
4 trialsNCT04165096 2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02439034 2026-03-16
KETOCOL
Centre Oscar Lambret
Phase 2 Completed
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed